Ophthalmology

32% of patients said they were going to stop treatment and decline further injections due to mismanaged expectations of discomfort and anxiety.

After receiving an average of 4.7 injections through year 1, patients received 0.9 injections in year 4, while maintaining gains in BCVA letters.

Overall, the data showed that patients in the treat-and-extend group also received fewer injections in comparison to the monthly group.

Color Doppler imaging showed that patients with AMD had general vascular disorder in all arteries evaluated.

Optical coherence tomography accrued savings of $9.0 billion for the US government through Medicare and an estimated $2.2 billion in savings for AMD patients since 2013.

Dr. Ianchulev discusses his breakthrough technology, miLOOP, that will revolutionize the way cataract surgery is performed and how doctors fragment the lens.

Unapproved stem cell therapies now bring in $2.4 billion per year. The FDA is working to ensure they follow regulatory, safety and efficacy guidelines.

Spark Therapeutics CEO Jeff Marrazzo reassured patients and the medical community he has an obligation to ensure access to the novel gene therapy.

Brimonidine was previously approved by the FDA in 1996 for the treatment of intraocular pressure reduction in patients with glaucoma.

This is the first gene therapy approved in the US targeting mutations in a specific gene.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

The distractive spots floating through fields of vision may have finally met their match.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

A study shows CRA presence has a negative correlation with the volume of SRF.

The FDA has approved Vyzulta 0.024% (latanoprostene bunod ophthalmic solution) as treatment to reduce intraocular pressure for patients with open-angle glaucoma or ocular hypertension

The committee voted 10-0 in favor of efficacy and 9-1 in favor of safety.

Results determined that 168 out of the 300 patients, or 56.0%, had felt "some type of anxiety" related to the anti-VEGF treatments.

The odds of late AMD were 41% lower among active individuals in comparison to sedentary individuals, according to the analysis.

Researchers found two loci, TRPM1 and ABHD2/RLBP1, with previously unrecognized associations related to the risk of age-related macular degeneration.

Rajeev Muni speaks about the 1-year results of a randomized trial comparing Pneumatic Retinopexy vs. Vitrectomy in the management of primary Rhegmatogenous Retinal Detachment.

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.